Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565564 | 0.84 | GRIA1 (0.45) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL7563841 | 0.78 | ALDH1A1 (0.46) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL27546229 | 0.75 | GRIA1 (0.33) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL9232038 | 0.71 | CNR2 (0.34) | SMN1; SMN2MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL3669653 | 0.71 | POLB (0.35) | MAPTGAAL3MBTL1 | |
| SCHEMBL7566388 | 0.71 | GRIA1 (0.49) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL10258517 | 0.68 | KDM4E (0.44) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL10556095 | 0.68 | ALDH1A1 (0.59) | SMN1; SMN2MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL3147669 | 0.67 | PPID (0.50) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL13222646 | 0.66 | SMN1; SMN2 (0.50) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1125818-C | Amino acid derivatives of substituted quinoxaline 2, 3 -dione derivativesa as glutamate receptor antagonists | WARNER LAMBERT CO (US) | 2003-10-29 | — | — | CN | disclosed |
| US-6455698-B1 | FOR TREATING CEREBRAL ISCHEMIA OR CEREBRAL INFARCTION RESULTING FROM THROMBOEMBOLIC OR HEMORRHAGIC STROKE, CEREBRAL VASOSPASMS, HYPOGLYCEMIA, CARDIAC ARREST, NEURODEGENERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| EP-0832074-B1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | KORNBERG BRIAN EDWARD (US) | 2002-05-30 | — | — | US | disclosed |
| US-6340758-B1 | DRUGS AS NEUROPROTECTIVE AGENTS INVENTION MAY ALSO BE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, EPILEPSY, ANXIETY, PAIN AND DRUG ADDICTION. | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| US-6268366-B1 | Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| US-6191134-B1 | STROKE THERAPY, ANTIISCHEMIC AGENTS, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2001-02-20 | — | — | US | disclosed |
| US-6172065-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2001-01-09 | — | — | US | disclosed |
| US-6096744-A | ANTICONVULSANTS | WARNER-LAMBERT COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| US-6015800-A | Substituted quinoxaline-2-ones as glutamate receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-01-18 | — | — | US | disclosed |
| CN-1187190-A | Amino acid derivatives of substituted quinoxaline 2, 3-dione derivatives as glutamate receptor antagonists | WARNER LAMBERT CO (US) | 1998-07-08 | — | — | CN | disclosed |
| WO-1998023599-A1 | UREA AND THIOUREA DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5614508-A | ANTIISCHEMIC AGENTS, ALZHEIMERS, STROKE OR NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1996040649-A1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | CBR1, CBR3, CHRNA7 | GRIA1 110/4885GRIA2 108/4885GRIA3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.